A neutral, harm-reduction look at ostarine, why it is the mildest of the SARMs, and what to monitor given it still suppresses natural hormones.
At a glance
Ostarine, known in development as MK-2866 or enobosarm, is generally considered the mildest and most-studied selective androgen receptor modulator (SARM). Under the name enobosarm it has been investigated in genuine clinical trials, including for muscle wasting and, more recently, as a treatment for androgen-receptor-positive, ER-positive breast cancer, where it has reached phase 3.
This is an educational tracking guide, not a recommendation. Despite the clinical research, ostarine is not an approved drug, and the products sold to consumers are unapproved research chemicals that are frequently mislabeled.
Even the mildest SARM suppresses the HPTA, can lower HDL cholesterol, and can stress the liver. Because consumer products are unregulated, mislabeling and contamination are common and are a leading cause of unexpected side effects. Bloodwork before, during, and after, plus consideration of post-cycle therapy, is the sensible baseline for anyone who has decided to use it.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.